+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncolytic Virus Therapies Market by Cancer Indication, Virus Type, Administration Route, End User - Global Forecast to 2030- Product Image
Oncolytic Virus Therapies Market by Cancer Indication, Virus Type, Administration Route, End User - Global Forecast to 2030- Product Image
Sale

Oncolytic Virus Therapies Market by Cancer Indication, Virus Type, Administration Route, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925124
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oncolytic virus therapies market is rapidly evolving, offering senior decision-makers targeted opportunities in cancer treatment where current modalities face limitations. This analysis delivers an in-depth view of key market trends, regulatory shifts, and technological advancements that are shaping next-generation virotherapies across major indications and global regions.

Market Snapshot: Oncolytic Virus Therapies Market

The Oncolytic Virus Therapies Market grew from USD 132.50 million in 2024 to USD 153.79 million in 2025. It is expected to continue growing at a CAGR of 15.93%, reaching USD 321.81 million by 2030. This growth is underpinned by sustained advances in viral vector engineering, increased investment in immuno-oncology, and broader regulatory acceptance across major healthcare markets. Rising clinical trial activity illustrates industry confidence, while global pipeline expansion indicates a maturing landscape with robust commercial prospects.

Scope & Segmentation

This report covers a comprehensive set of segments and regions, facilitating strategic planning for sector leaders:

  • Cancer Indication: Glioblastoma, Head and Neck Cancer, Melanoma
  • Virus Type: Genetically Modified Viruses (Adenovirus, Herpes Simplex Virus, Vaccinia Virus), Wild Type Viruses
  • Administration Route: Intratumoral, Intravenous
  • End User: Hospitals, Research Institutes, Specialty Clinics
  • Regional Coverage: Americas (including United States by key states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, key markets in Africa and the Gulf region), and Asia-Pacific (covering China, India, Japan, Australia, South Korea, ASEAN, and related growth hubs)
  • Leading Companies Profiled: Amgen Inc., Merck & Co., Inc., Replimune Group, Inc., Oncolytics Biotech Inc., Sorrento Therapeutics, Inc., Transgene SA, PsiOxus Therapeutics Ltd, OncoSec Medical Incorporated, Targovax ASA, SillaJen, Inc.
  • Technology Trends: CRISPR-based genome editing, synthetic biology in vector design, nanoparticle encapsulation, real-time virus-tumor interaction modeling

Key Takeaways for Senior Decision-Makers

  • Synergistic combinations of oncolytic viruses with checkpoint inhibitors and cell-based immunotherapies are expanding potential indications, emphasizing the strategic importance of platform versatility.
  • Pivotal advances in replication control, transgene payloads, and safety engineering are driving late-stage clinical progress and regulatory buy-in across diverse regions.
  • Hospitals leading initial treatment adoption and research institutes driving early-phase innovations create a dual-market dynamic that executives should align with their commercialization strategies.
  • Collaboration between biopharmaceutical firms, specialized biotechs, and contract manufacturers continues to strengthen supply chain resilience and process scalability.
  • Diversified portfolios—including administration routes and virus backbones—will improve risk management as new policy frameworks and reimbursement models come online globally.

Tariff Impact: Strategic Considerations

Imminent United States tariffs are set to impact costs across key manufacturing components such as disposable assemblies, culture media, and automation equipment. This may force developers to reevaluate supplier networks, invest in domestic production, or partner regionally to maintain supply continuity. These tariffs could also drive shifts toward agile trial design and manufacturing localization to optimize costs and timelines.

Methodology & Data Sources

This report utilizes a multi-methodology approach comprising interviews with subject matter experts, analysis of peer-reviewed literature, and in-depth review of clinical trial registries. Regulatory documents were thoroughly examined to evaluate adaptive trial designs, regional policy evolution, and tariff considerations specific to the oncolytic virus therapies market. Data triangulation and ongoing peer review ensure relevance and accuracy for stakeholders.

Why This Report Matters

  • Enables executive-level decision-makers to effectively benchmark therapeutic strategies, supply chain choices, and regional market entry plans.
  • Delivers actionable insights on evolving regulatory requirements and collaboration models, essential for navigating upcoming tariffs and policy shifts.
  • Empowers stakeholders with clarity on segmentation trends, innovative technology adoption, and partnership opportunities in high-growth corridors.

Conclusion

Oncolytic virus therapies are positioned for significant advancement as technology, clinical research, and policy coalesce across global markets. Senior leaders will benefit from informed strategies and adaptive planning to capture emerging opportunities and respond to evolving challenges in this dynamic sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oncolytic Virus Therapies Market, by Cancer Indication
8.1. Introduction
8.2. Glioblastoma
8.3. Head and Neck Cancer
8.4. Melanoma
9. Oncolytic Virus Therapies Market, by Virus Type
9.1. Introduction
9.2. Genetically Modified Virus
9.2.1. Adenovirus
9.2.2. Herpes Simplex Virus
9.2.3. Vaccinia Virus
9.3. Wild Type Virus
10. Oncolytic Virus Therapies Market, by Administration Route
10.1. Introduction
10.2. Intratumoral
10.3. Intravenous
11. Oncolytic Virus Therapies Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Research Institutes
11.4. Specialty Clinics
12. Americas Oncolytic Virus Therapies Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Oncolytic Virus Therapies Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Oncolytic Virus Therapies Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Amgen Inc.
15.3.2. Merck & Co., Inc.
15.3.3. Replimune Group, Inc.
15.3.4. Oncolytics Biotech Inc.
15.3.5. Sorrento Therapeutics, Inc.
15.3.6. Transgene SA
15.3.7. PsiOxus Therapeutics Ltd
15.3.8. OncoSec Medical Incorporated
15.3.9. Targovax ASA
15.3.10. SillaJen, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ONCOLYTIC VIRUS THERAPIES MARKET MULTI-CURRENCY
FIGURE 2. ONCOLYTIC VIRUS THERAPIES MARKET MULTI-LANGUAGE
FIGURE 3. ONCOLYTIC VIRUS THERAPIES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ONCOLYTIC VIRUS THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 37. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 39. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 40. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 44. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 45. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 63. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 65. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 66. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 68. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 69. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 70. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 71. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 73. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 74. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 75. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 76. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 78. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 79. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 83. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 84. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 85. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 86. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 88. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 89. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 90. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 91. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 93. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 98. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 99. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 100. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 103. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 104. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 105. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 108. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 110. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 111. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 114. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 115. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 118. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 119. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 120. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 121. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 123. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 124. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 125. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 126. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 133. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 134. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 138. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 140. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 141. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 143. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 144. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 145. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 146. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 148. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 149. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 150. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 153. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 154. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 155. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 156. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 158. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 159. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 160. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 161. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 163. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 164. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 165. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 166. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 174. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 175. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 176. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 177. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 179. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 180. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 181. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 182. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 184. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 185. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 186. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 187. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 194. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 195. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 204. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 205. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 206. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 207. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 224. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 225. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
TABLE 234. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Oncolytic Virus Therapies market report include:
  • Amgen Inc.
  • Merck & Co., Inc.
  • Replimune Group, Inc.
  • Oncolytics Biotech Inc.
  • Sorrento Therapeutics, Inc.
  • Transgene SA
  • PsiOxus Therapeutics Ltd
  • OncoSec Medical Incorporated
  • Targovax ASA
  • SillaJen, Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 153.79 Million
Forecasted Market Value ( USD ) by 2030 $ 321.81 Million
Compound Annual Growth Rate15.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Oncolytic Virus Cancer Therapy Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Oncolytic Virus Cancer Therapy Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Oncolytic Virus Therapies Market Report by Virus Type, Application, End Use, and Region 2025-2033 - Product Image

Oncolytic Virus Therapies Market Report by Virus Type, Application, End Use, and Region 2025-2033

  • Report
  • 133 Pages
  • Global
From
Oncolytic Virus Cancer Therapy Pipeline Analysis Report 2025 - Product Image

Oncolytic Virus Cancer Therapy Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Oncolytic Virus Immunotherapy - Global Strategic Business Report - Product Image

Oncolytic Virus Immunotherapy - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Oncolytic Virus Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Oncolytic Virus Drug Market

The Oncolytic Virus Drug market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Oncolytic virus drugs are a type of biologic therapy that uses viruses to target and destroy cancer cells. These drugs are designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. They can be used alone or in combination with other treatments such as chemotherapy or radiation therapy. Oncolytic virus drugs have the potential to improve the efficacy of existing treatments and reduce the side effects associated with them. Some companies in the Oncolytic Virus Drug market include Amgen, Merck, Pfizer, and Novartis. These companies are actively researching and developing new oncolytic virus drugs to treat a variety of cancers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.